Immunomodulatory effects of bendamustine in hematopoietic cell transplantation

Jessica Stokes, Megan S. Molina, Emely A. Hoffman, Richard J. Simpson, Emmanuel Katsanis

Research output: Contribution to journalReview articlepeer-review

8 Scopus citations


Bendamustine (BEN) is a unique alkylating agent with efficacy against a broad range of hematological malignancies, although investigations have only recently started to delve into its immunomodulatory effects. These immunomodulatory properties of BEN in the context of hematopoietic cell transplantation (HCT) are reviewed here. Pre-and post-transplant use of BEN in multiple murine models have consistently resulted in reduced GvHD and enhanced GvL, with significant changes to key immunological cell populations, including T-cells, myeloid derived sup-pressor cells (MDSCs), and dendritic cells (DCs). Further, in vitro studies find that BEN enhances the suppressive function of MDSCs, skews DCs toward cDC1s, enhances Flt3 expression on DCs, increases B-cell production of IL-10, inhibits STAT3 activation, and suppresses proliferation of T-and B-cells. Overall, BEN has a broad range of immunomodulatory effects that, as they are further elucidated, may be exploited to improve clinical outcomes. As such, clinical trials are currently underway investigating new potential applications of BEN in the setting of allogeneic HCT.

Original languageEnglish (US)
Article number1702
Issue number7
StatePublished - Apr 1 2021


  • Bendamustine
  • Hematopoietic cell transplantation

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Immunomodulatory effects of bendamustine in hematopoietic cell transplantation'. Together they form a unique fingerprint.

Cite this